Inhibiting insulin-mediated β 2-adrenergic receptor activation prevents diabetes-associated cardiac dysfunction

Circulation

Volumn 135, Issue 1, 2017, Pages 73-88

  Wang, Qingtong ^a,b   Liu, Yongming ^a,c   Fu, Qin ^a,d   Xu, Bing ^a   Zhang, Yuan ^e   Kim, Sungjin ^a   Tan, Ruensern ^a   Barbagallo, Federica ^a   West, Toni ^a   Anderson, Ethan ^f   Wei, Wei ^b   Abel, E Dale ^e   Xiang, Yang K ^a,g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ANHUI MEDICAL UNIVERSITY   (China)

^c SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^d HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^e UNIVERSITY OF IOWA   (United States)

^f EAST CAROLINA UNIVERSITY   (United States)

^g VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

Author keywords

diabetic cardiomyopathy; heart failure; insulin; phosphodiesterase; adrenergic receptors

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA ARRESTIN 2; CARVEDILOL; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; FLUOXETINE; G PROTEIN COUPLED RECEPTOR KINASE 2; GLUCOSE; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; INSULIN; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PAROXETINE; PHOSPHODIESTERASE; PHOSPHODIESTERASE IIA; PHOSPHODIESTERASE IIIA; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IVA; PHOSPHODIESTERASE IVB; PHOSPHODIESTERASE IVD; PHOSPHODIESTERASE VA; PHOSPHOLAMBAN; ROLIPRAM; TIMOLOL; TROPONIN I; UNCLASSIFIED DRUG; CARBAZOLE DERIVATIVE; PROPANOLAMINE DERIVATIVE; VASODILATOR AGENT;

ADULT; ADVERSE OUTCOME; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC CARDIOMYOPATHY; DIABETIC PATIENT; DIASTOLIC DYSFUNCTION; DIET INDUCED OBESITY; DRUG EFFICACY; DRUG MECHANISM; GENE DELETION; GENE EXPRESSION; HEART FAILURE; HEART MUSCLE CONTRACTILITY; HEART PROTECTION; HUMAN; HUMAN TISSUE; HYPERINSULINEMIA; INSULIN RELEASE; LIPID DIET; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; SYSTOLIC DYSFUNCTION; TRANSACTIVATION; WILD TYPE MOUSE; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CARDIAC MUSCLE; CARDIAC MUSCLE CELL; CELL CULTURE; COMPLICATION; CYTOLOGY; DEFICIENCY; DRUG EFFECTS; GENETICS; HEART CONTRACTION; KNOCKOUT MOUSE; METABOLISM; OBESITY;

ANIMALS; BETA-ARRESTIN 2; CARBAZOLES; CELLS, CULTURED; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; G-PROTEIN-COUPLED RECEPTOR KINASE 2; HEART FAILURE; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCARDIAL CONTRACTION; MYOCARDIUM; MYOCYTES, CARDIAC; OBESITY; PROPANOLAMINES; RECEPTORS, ADRENERGIC, BETA-2; SIGNAL TRANSDUCTION; VASODILATOR AGENTS;

EID: 84997040259     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.116.022281     Document Type: Article

References (50)

1. Gregg EW, Li Y, Wang J, Burrows NR, Ali MK, Rolka D, Williams DE, Geiss L, Changes in diabetes-related complications in the United States, 1990-2010. N Engl J Med 2014 370 1514 1523. doi: 10.1056/NEJMoa1310799.
2. Bugger H, Abel ED, Molecular mechanisms of diabetic cardiomyopathy. Diabetologia 2014 57 660 671
3. Hayat SA, Patel B, Khattar RS, Malik RA, Diabetic cardiomyopathy: mechanisms, diagnosis and treatment. Clin Sci (Lond) 2004 107 539 557. doi: 10.1042/CS20040057.
4. Boudina S, Abel ED, Diabetic cardiomyopathy revisited. Circulation 2007 115 3213 3223
5. Abel ED, O'Shea KM, Ramasamy R, Insulin resistance: metabolic mechanisms and consequences in the heart. Arteriosclerosis, thrombosis, and vascular biology 2012 32 2068 2076
6. Taegtmeyer H, Beauloye C, Harmancey R, Hue L, Insulin resistance protects the heart from fuel overload in dysregulated metabolic states. Am J Physiol Heart Circ Physiol 2013 305 H1693 H1697. doi: 10.1152/ajpheart.00854.2012.
7. Shimizu I, Minamino T, Toko H, Okada S, Ikeda H, Yasuda N, Tateno K, Moriya J, Yokoyama M, Nojima A, Koh GY, Akazawa H, Shiojima I, Kahn CR, Abel ED, Komuro I, Excessive cardiac insulin signaling exacerbates systolic dysfunction induced by pressure overload in rodents. J Clin Invest 2010 120 1506 1514
8. Wende AR, O'Neill BT, Bugger H, Riehle C, Tuinei J, Buchanan J, Tsushima K, Wang L, Caro P, Guo A, Sloan C, Kim BJ, Wang X, Pereira RO, McCrory MA, Nye BG, Benavides GA, Darley-Usmar VM, Shioi T, Weimer BC, Abel ED, Enhanced cardiac Akt/protein kinase B signaling contributes to pathological cardiac hypertrophy in part by impairing mitochondrial function via transcriptional repression of mitochondrion-Targeted nuclear genes. Molecular and cellular biology 2015 35 831 846
9. Cook SA, Varela-Carver A, Mongillo M, Kleinert C, Khan MT, Leccisotti L, Strickland N, Matsui T, Das S, Rosenzweig A, Punjabi P, Camici PG, Abnormal myocardial insulin signalling in type 2 diabetes and left-ventricular dysfunction. Eur Heart J 2010 31 100 111. doi: 10.1093/eurheartj/ehp396.
10. Battiprolu PK, Hojayev B, Jiang N, Wang ZV, Luo X, Iglewski M, Shelton JM, Gerard RD, Rothermel BA, Gillette TG, Lavandero S, Hill JA, Metabolic stress-induced activation of FoxO1 triggers diabetic cardiomyopathy in mice. J Clin Invest 2012 122 1109 1118. doi: 10.1172/JCI60329.
11. Qi Y, Zhu Q, Zhang K, Thomas C, Wu Y, Kumar R, Baker KM, Xu Z, Chen S, Guo S, Activation of Foxo1 by insulin resistance promotes cardiac dysfunction and β-myosin heavy chain gene expression. Circ Heart Fail 2015 8 198 208. doi: 10.1161/CIRCHEARTFAILURE.114.001457.
12. Qi Y, Xu Z, Zhu Q, Thomas C, Kumar R, Feng H, Dostal DE, White MF, Baker KM, Guo S, Myocardial loss of IRS1 and IRS2 causes heart failure and is controlled by p38α MAPK during insulin resistance. Diabetes 2013 62 3887 3900. doi: 10.2337/db13-0095.
13. Bell DS, Heart failure: the frequent, forgotten, and often fatal complication of diabetes. Diabetes Care 2003 26 2433 2441
14. Ganguly PK, Pierce GN, Dhalla KS, Dhalla NS, Defective sarcoplasmic reticular calcium transport in diabetic cardiomyopathy. Am J Physiol 1983 244 E528 E535
15. Giacomelli F, Wiener J, Primary myocardial disease in the diabetic mouse: an ultrastructural study. Lab Invest 1979 40 460 473
16. Bell DS, Diabetic cardiomyopathy: a unique entity or a complication of coronary artery disease? Diabetes Care 1995 18 708 714
17. Fu Q, Xu B, Liu Y, Parikh D, Li J, Li Y, Zhang Y, Riehle C, Zhu Y, Rawlings T, Shi Q, Clark RB, Chen X, Abel ED, Xiang YK, Insulin inhibits cardiac contractility by inducing a Gi-biased beta2-Adrenergic signaling in hearts. Diabetes 2014 63 2676 2689
18. Nichols GA, Hillier TA, Erbey JR, Brown JB, Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care 2001 24 1614 1619
19. Castagno D, Baird-Gunning J, Jhund PS, Biondi-Zoccai G, MacDonald MR, Petrie MC, Gaita F, McMurray JJ, Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: evidence from a 37 229 patient meta-Analysis. Am Heart J 2011 162 938.e2 948.e2. doi: 10.1016/j.ahj.2011.07.030.
20. Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, Udell JA, Mosenzon O, Im K, Umez-Eronini AA, Pollack PS, Hirshberg B, Frederich R, Lewis BS, McGuire DK, Davidson J, Steg PG, Bhatt DL, SAVOR-TIMI 53 Steering Committee and Investigators∗ Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation 2014 130 1579 1588. doi: 10.1161/CIRCULATIONAHA.114.010389.
21. Smooke S, Horwich TB, Fonarow GC, Insulin-Treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure. Am Heart J 2005 149 168 174. doi: 10.1016/j.ahj.2004.07.005.
22. Deedwania PC, Giles TD, Klibaner M, Ghali JK, Herlitz J, Hildebrandt P, Kjekshus J, Spinar J, Vitovec J, Stanbrook H, Wikstrand J, MERIT-HF Study Group Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF. Am Heart J 2005 149 159 167. doi: 10.1016/j.ahj.2004.05.056.
23. Bell DS, Lukas MA, Holdbrook FK, Fowler MB, The effect of carvedilol on mortality risk in heart failure patients with diabetes: results of a meta-Analysis. Curr Med Res Opin 2006 22 287 296. doi: 10.1185/030079906X80459.
24. Torp-Pedersen C, Metra M, Charlesworth A, Spark P, Lukas MA, Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Remme WJ, Scherhag A, COMET investigators Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol or Metoprolol European Trial (COMET). Heart 2007 93 968 973. doi: 10.1136/hrt.2006.092379.
25. Belke DD, Betuing S, Tuttle MJ, Graveleau C, Young ME, Pham M, Zhang D, Cooksey RC, McClain DA, Litwin SE, Taegtmeyer H, Severson D, Kahn CR, Abel ED, Insulin signaling coordinately regulates cardiac size, metabolism, and contractile protein isoform expression. J Clin Invest 2002 109 629 639
26. Shiojima I, Yefremashvili M, Luo Z, Kureishi Y, Takahashi A, Tao J, Rosenzweig A, Kahn CR, Abel ED, Walsh K, Akt signaling mediates postnatal heart growth in response to insulin and nutritional status. J Biol Chem 2002 277 37670 37677
27. Laustsen PG, Russell SJ, Cui L, Entingh-Pearsall A, Holzenberger M, Liao R, Kahn CR, Essential role of insulin and insulin-like growth factor 1 receptor signaling in cardiac development and function. Mol Cell Biol 2007 27 1649 1664. doi: 10.1128/MCB.01110-06.
28. Xiang Y, Kobilka BK, Myocyte adrenoceptor signaling pathways. Science 2003 300 1530 1532. doi: 10.1126/science.1079206.
29. Xiao RP, Zhu W, Zheng M, Cao C, Zhang Y, Lakatta EG, Han Q, Subtype-specific alpha1- And beta-Adrenoceptor signaling in the heart. Trends Pharmacol Sci 2006 27 330 337. doi: 10.1016/j.tips.2006.04.009.
30. Perrino C, Rockman HA, Reversal of cardiac remodeling by modulation of adrenergic receptors: a new frontier in heart failure. Curr Opin Cardiol 2007 22 443 449. doi: 10.1097/HCO.0b013e3282294d72.
31. Brittsan AG, Kranias EG, Phospholamban and cardiac contractile function. J Mol Cell Cardiol 2000 32 2131 2139. doi: 10.1006/jmcc.2000.1270.
32. Fu Q, Xu B, Parikh D, Cervantes D, Xiang YK, Insulin induces IRS2-dependent and GRK2-mediated β2AR internalization to attenuate βAR signaling in cardiomyocytes. Cell Signal 2015 27 707 715. doi: 10.1016/j.cellsig.2014.11.018.
33. Xiang Y, Naro F, Zoudilova M, Jin SL, Conti M, Kobilka B, Phosphodiesterase 4D is required for beta2 adrenoceptor subtype-specific signaling in cardiac myocytes. Proc Natl Acad Sci U S A 2005 102 909 914. doi: 10.1073/pnas.0405263102.
34. Richter W, Day P, Agrawal R, Bruss MD, Granier S, Wang YL, Rasmussen SG, Horner K, Wang P, Lei T, Patterson AJ, Kobilka B, Conti M, Signaling from beta1- And beta2-Adrenergic receptors is defined by differential interactions with PDE4. EMBO J 2008 27 384 393. doi: 10.1038/sj.emboj.7601968.
35. Lin FT, Miller WE, Luttrell LM, Lefkowitz RJ, Feedback regulation of beta-Arrestin1 function by extracellular signal-regulated kinases. J Biol Chem 1999 274 15971 15974
36. Thal DM, Homan KT, Chen J, Wu EK, Hinkle PM, Huang ZM, Chuprun JK, Song J, Gao E, Cheung JY, Sklar LA, Koch WJ, Tesmer JJ, Paroxetine is a direct inhibitor of g protein-coupled receptor kinase 2 and increases myocardial contractility. ACS Chem Biol 2012 7 1830 1839. doi: 10.1021/cb3003013.
37. Schumacher SM, Gao E, Zhu W, Chen X, Chuprun JK, Feldman AM, Tesmer JJ, Koch WJ, Paroxetine-mediated GRK2 inhibition reverses cardiac dysfunction and remodeling after myocardial infarction. Sci Transl Med 2015 7 277ra31. doi: 10.1126/scitranslmed.aaa0154.
38. Després JP, Lamarche B, Mauriège P, Cantin B, Lupien PJ, Dagenais GR, Risk factors for ischaemic heart disease: is it time to measure insulin? Eur Heart J 1996 17 1453 1454
39. Pyörälä M, Miettinen H, Laakso M, Pyörälä K, Hyperinsulinemia predicts coronary heart disease risk in healthy middle-Aged men: the 22-year follow-up results of the Helsinki Policemen Study. Circulation 1998 98 398 404
40. Garcia-Guerra L, Nieto-Vazquez I, Vila-Bedmar R, Jurado-Pueyo M, Zalba G, Díez J, Murga C, Fernández-Veledo S, Mayor F Jr, Lorenzo M, G protein-coupled receptor kinase 2 plays a relevant role in insulin resistance and obesity. Diabetes 2010 59 2407 2417. doi: 10.2337/db10-0771.
41. Vila-Bedmar R, Cruces-Sande M, Lucas E, Willemen HL, Heijnen CJ, Kavelaars A, Mayor F Jr, Murga C, Reversal of diet-induced obesity and insulin resistance by inducible genetic ablation of GRK2. Sci Signal 2015 8 ra73. doi: 10.1126/scisignal.aaa4374.
42. Lehnart SE, Wehrens XH, Reiken S, Warrier S, Belevych AE, Harvey RD, Richter W, Jin SL, Conti M, Marks AR, Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias. Cell 2005 123 25 35. doi: 10.1016/j.cell.2005.07.030.
43. Beca S, Helli PB, Simpson JA, Zhao D, Farman GP, Jones PP, Tian X, Wilson LS, Ahmad F, Chen SR, Movsesian MA, Manganiello V, Maurice DH, Conti M, Backx PH, Phosphodiesterase 4D regulates baseline sarcoplasmic reticulum Ca2+ release and cardiac contractility, independently of L-Type Ca2+ current. Circ Res 2011 109 1024 1030. doi: 10.1161/CIRCRESAHA.111.250464.
44. Ghigo A, Perino A, Mehel H, Zahradníková A Jr, Morello F, Leroy J, Nikolaev VO, Damilano F, Cimino J, De Luca E, Richter W, Westenbroek R, Catterall WA, Zhang J, Yan C, Conti M, Gomez AM, Vandecasteele G, Hirsch E, Fischmeister R, Phosphoinositide 3-kinase γ protects against catecholamine-induced ventricular arrhythmia through protein kinase A-mediated regulation of distinct phosphodiesterases. Circulation 2012 126 2073 2083. doi: 10.1161/CIRCULATIONAHA.112.114074.
45. Leroy J, Abi-Gerges A, Nikolaev VO, Richter W, Lechêne P, Mazet JL, Conti M, Fischmeister R, Vandecasteele G, Spatiotemporal dynamics of beta-Adrenergic cAMP signals and L-Type Ca2+ channel regulation in adult rat ventricular myocytes: role of phosphodiesterases. Circ Res 2008 102 1091 1100. doi: 10.1161/CIRCRESAHA.107.167817.
46. 2+ current and protects against ventricular arrhythmias in mice. J Clin Invest 2011 121 2651 2661. doi: 10.1172/JCI44747.
47. Timofeyev V, Myers RE, Kim HJ, Woltz RL, Sirish P, Heiserman JP, Li N, Singapuri A, Tang T, Yarov-Yarovoy V, Yamoah EN, Hammond HK, Chiamvimonvat N, Adenylyl cyclase subtype-specific compartmentalization: differential regulation of L-Type Ca2+ current in ventricular myocytes. Circ Res 2013 112 1567 1576. doi: 10.1161/CIRCRESAHA.112.300370.
48. Richter W, Xie M, Scheitrum C, Krall J, Movsesian MA, Conti M, Conserved expression and functions of PDE4 in rodent and human heart. Basic Res Cardiol 2011 106 249 262. doi: 10.1007/s00395-010-0138-8.
49. Abi-Gerges A, Richter W, Lefebvre F, Mateo P, Varin A, Heymes C, Samuel JL, Lugnier C, Conti M, Fischmeister R, Vandecasteele G, Decreased expression and activity of cAMP phosphodiesterases in cardiac hypertrophy and its impact on beta-Adrenergic cAMP signals. Circ Res 2009 105 784 792. doi: 10.1161/CIRCRESAHA.109.197947.
50. Haas SJ, Vos T, Gilbert RE, Krum H, Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-Analysis of large-scale clinical trials. Am Heart J 2003 146 848 853. doi: 10.1016/S0002-8703(03)00403-4.